JP2017537055A - カンプトテシン類似体合成のための方法およびシステム - Google Patents
カンプトテシン類似体合成のための方法およびシステム Download PDFInfo
- Publication number
- JP2017537055A JP2017537055A JP2017515247A JP2017515247A JP2017537055A JP 2017537055 A JP2017537055 A JP 2017537055A JP 2017515247 A JP2017515247 A JP 2017515247A JP 2017515247 A JP2017515247 A JP 2017515247A JP 2017537055 A JP2017537055 A JP 2017537055A
- Authority
- JP
- Japan
- Prior art keywords
- synthesis
- solution
- mmol
- exemplary
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract description 12
- 230000015572 biosynthetic process Effects 0.000 title description 34
- 238000003786 synthesis reaction Methods 0.000 title description 34
- 239000000203 mixture Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims description 4
- VEPTXBCIDSFGBF-UHFFFAOYSA-M tetrabutylazanium;fluoride;trihydrate Chemical compound O.O.O.[F-].CCCC[N+](CCCC)(CCCC)CCCC VEPTXBCIDSFGBF-UHFFFAOYSA-M 0.000 claims description 4
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 claims description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 abstract description 4
- 229920002994 synthetic fiber Polymers 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000010189 synthetic method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VOYADQIFGGIKAT-UHFFFAOYSA-N 1,3-dibutyl-4-hydroxy-2,6-dioxopyrimidine-5-carboximidamide Chemical compound CCCCn1c(O)c(C(N)=N)c(=O)n(CCCC)c1=O VOYADQIFGGIKAT-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
- C07F7/083—Syntheses without formation of a Si-C bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
式中、R1〜R11は、978特許におけるように定義される(例えば、第3欄、第35行目〜第4欄、第65行目)。
式I
式中、R1〜R11は、978特許におけるように定義される(例えば、第3欄、第35行目〜第4欄、第65行目)。
1H NMR (300 MHz,CDCl3) δ 7.20(t,J=7.8Hz,1H),7.02(d,J=7.8Hz,1H),6.96(d,J=2.1Hz,1H),6.77(dd,J=7.8,2.1Hz,1H),5.12(s,1H),4.89(s,1H),3.02(m,2H),2.92(m,2H),2.16(m,1H),1.95(m,1H)(図2)。
1H NMR (300 MHz,CDCl3) δ 7.20(t,J=7.8Hz,1H),7.06(d,J=7.8Hz,1H),6.98(t,J=1.8Hz,1H),6.77(dd,J=7.8,1.8Hz,1H),5.12(s,1H),3.07(m,2H),2.94(m,2H),2.17(m,1H),1.98(m,1H),1.02(s,9H),0.23(s,6H)(図3)。
1H NMR (300 MHz,CDCl3) δ 7.57(d,J=7.8Hz,1H),7.50(d,J=2.1Hz,1H),7.21(t,J=7.8Hz,1H),6.67(dd,J=7.8,2.1Hz,1H),2.83(m,2H),2.42(m,2H),2.07(m,1H),1.88(m,1H),1.00(s,9H),0.83(s,9H),0.23(s,6H),0.16(s,9H)(図4)。
1H NMR (300 MHz, CDCl3) δ 7.41(d,J=7.8Hz,1H),7.32(t,J=7.8Hz,1H),7.23(s,1H),6.99(d,J=5.7Hz,1H),0.99(s,9H),0.96(s,9H),0.36(s,6H),0.21(s,9H)(図5)。
1H NMR (300 MHz, CDCl3) δ 7.40(m,1H),7.32(m,2H),7.04(d,J=5.4Hz,1H),6.04(s,1H),0.96(s,9H),0.37(s,6H)(図6)。
1H NMR (300 MHz,CDCl3) δ 8.07(d,J=9.0Hz,1H),7.99(s,br,1H),6.90(dd,J=2.7,9.0Hz,1H),6.51(d,J=2.7Hz,1H),0.96(s,9H),0.19(s,6H)(図7)。
1H NMR (300 MHz,DMSO−d6) δ 8.76(s,1H),7.12(d,J=2.7Hz,1H),6.76(m,3H),6.60(d,J=8.7Hz,1H),0.91(s,9H),0.31(s,6H)(図8).LCMS:M+1=252(図9)。
1H NMR (300 MHz,DMSO−d6) δ 10.35(s,1H),8.02(d,J=9.0Hz,1H),7.56(s,1H),7.39(d,J=9.0Hz,1H),7.26(s,1H),6.48(s,1H),5.40(s,2H),5.21(s,2H),1.85(m,2H),0.96(s,9H),0.87(t,J=7.2Hz,3H),0.65(s,6H)(図10)。HPLC純度:99.1%(図11)。キラルHPLC純度:>99%(図12)。
1H NMR (300 MHz,DMSO−d6) δ 10.35(s,1H),8.03(d,J=9.0Hz,1H),7.56(d,J=2.4Hz,1H),7.38(dd,J=2.4,9.0Hz,1H),7.26(s,1H),6.48(s,1H),5.40(s,2H),5.21(s,2H),1.85(m,2H),0.96(s,9H),0.87(t,J=7.2Hz,3H),0.65(s,6H)(図13)。
Claims (1)
- 化合物AR−67を生成する方法であって、
プロパン−1,3−ジチオールおよび3−ヒドロキシベンズアルデヒドからAP4622−1を形成する工程;
TBSClの溶液をAP4622−1とイミダゾールとの溶液に添加し、AP4622−2を形成する工程;
n−BuLiをAP4622−2の溶液に添加して第1混合物を形成し、TBSClを該混合物に添加してAP4622−3を形成する工程;
AP4622−3の溶液をNBSの溶液に添加し、AP4622−4を形成する工程;
フッ化テトラブチルアンモニウム三水和物をAP4622−4の溶液に添加し、AP4622−5を形成する工程;
HNO3をAP4622−5の溶液に添加し、AP4622−6を形成する工程;
スズ粉末をAP4622−6の混合物に添加し、AP4622を形成する工程;および
AP4622、s−トリオンをTsOHの存在下で混合し、AR−67を形成する工程
を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462067065P | 2014-10-22 | 2014-10-22 | |
US62/067,065 | 2014-10-22 | ||
PCT/US2015/056499 WO2016064900A1 (en) | 2014-10-22 | 2015-10-20 | Methods and systems for camptothecin analog synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017537055A true JP2017537055A (ja) | 2017-12-14 |
JP6649368B2 JP6649368B2 (ja) | 2020-02-19 |
Family
ID=55761434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017515247A Active JP6649368B2 (ja) | 2014-10-22 | 2015-10-20 | カンプトテシン類似体合成のための方法およびシステム |
Country Status (9)
Country | Link |
---|---|
US (1) | US9447126B2 (ja) |
EP (1) | EP3209666B1 (ja) |
JP (1) | JP6649368B2 (ja) |
KR (1) | KR102399991B1 (ja) |
CN (1) | CN107428770B (ja) |
EA (1) | EA032135B1 (ja) |
ES (1) | ES2754649T3 (ja) |
SG (1) | SG11201702105QA (ja) |
WO (1) | WO2016064900A1 (ja) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150343A (en) * | 1993-06-30 | 2000-11-21 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
KR960029336A (ko) * | 1995-01-09 | 1996-08-17 | 김충환 | 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제 |
TWI245768B (en) * | 2001-02-21 | 2005-12-21 | Yakult Honsha Kk | Process for synthesizing camptothecin related compound(s) |
US6372906B1 (en) * | 2001-04-12 | 2002-04-16 | University Of Pittsburgh | Synthesis of silyl camptothecins and silyl homocamptothecins |
US7910737B2 (en) | 2005-02-07 | 2011-03-22 | Fermion Oy | Process for the manufacturing of 7-ethyl-10-hydroxy camptothecin |
JP2011184327A (ja) * | 2010-03-05 | 2011-09-22 | Eiweiss Kk | アシルシランの製造方法 |
US8722886B1 (en) * | 2012-11-13 | 2014-05-13 | Bionumerik Pharmaceuticals, Inc. | Methods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin |
CN103784965B (zh) * | 2014-01-14 | 2016-01-20 | 国家纳米科学中心 | 羟基喜树碱纳米脂束制剂及其制备方法 |
-
2015
- 2015-10-20 JP JP2017515247A patent/JP6649368B2/ja active Active
- 2015-10-20 ES ES15852329T patent/ES2754649T3/es active Active
- 2015-10-20 WO PCT/US2015/056499 patent/WO2016064900A1/en active Application Filing
- 2015-10-20 US US14/918,263 patent/US9447126B2/en active Active
- 2015-10-20 CN CN201580055562.9A patent/CN107428770B/zh active Active
- 2015-10-20 EA EA201790394A patent/EA032135B1/ru unknown
- 2015-10-20 KR KR1020177010122A patent/KR102399991B1/ko active IP Right Grant
- 2015-10-20 EP EP15852329.0A patent/EP3209666B1/en active Active
- 2015-10-20 SG SG11201702105QA patent/SG11201702105QA/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN107428770A (zh) | 2017-12-01 |
KR20170091086A (ko) | 2017-08-08 |
JP6649368B2 (ja) | 2020-02-19 |
EP3209666A4 (en) | 2018-05-23 |
CN107428770B (zh) | 2019-10-01 |
EP3209666A1 (en) | 2017-08-30 |
KR102399991B1 (ko) | 2022-05-18 |
WO2016064900A1 (en) | 2016-04-28 |
EA201790394A1 (ru) | 2017-08-31 |
SG11201702105QA (en) | 2017-05-30 |
US20160115183A1 (en) | 2016-04-28 |
ES2754649T3 (es) | 2020-04-20 |
EA032135B1 (ru) | 2019-04-30 |
US9447126B2 (en) | 2016-09-20 |
EP3209666B1 (en) | 2019-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101934096B1 (ko) | 이델라리십의 제조방법 | |
JP2018535262A (ja) | 4−((6−(2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−オキソエチル)ピリジン−3−イル)オキシ)ベンゾニトリル及び製造方法 | |
US10919847B2 (en) | Process for the preparation of arylsulfonylpropenenitriles by photocatalytic reactions | |
JP6649368B2 (ja) | カンプトテシン類似体合成のための方法およびシステム | |
JP4756608B2 (ja) | α−アミノホスホン酸エステル誘導体の製造方法 | |
Kurkutov et al. | Rearrangements in methanolysis of bis (2-bromoalkyl) selenides | |
JP2016198736A (ja) | アミノサリチルアルジミン配位子を金属に配位させた触媒及びこれを用いたヨード環化体の製造方法 | |
JPWO2018220888A1 (ja) | Pge1コアブロック誘導体およびその製造方法 | |
CN104059075B (zh) | 8,9-单,双取代的咪唑[1,2-c]-喹唑啉-3(2H)-酮稠杂环化合物及其制备方法 | |
CN109970764B (zh) | 一种(S)-1,1,5,5-四甲基二氢恶唑并[3,4-c]恶唑-3-酮的合成方法 | |
Zhang et al. | An enantioselective total synthesis of natural antibiotic marasin | |
Khisamutdinov et al. | Fluorination of 4-nitroisoxazoline salts. Synthesis of 4-fluoro-4-nitroisoxazolines and 4-fluoroisoxazoles | |
JP2020503336A (ja) | 殺有害生物化合物の調製方法 | |
KR101453413B1 (ko) | 알파-카르볼린 유도체의 제조방법 | |
KR102436114B1 (ko) | 신규한 이노토디올의 제조방법 | |
JP4643474B2 (ja) | 1置換コハク酸イミドの製造方法 | |
JP2016150913A5 (ja) | ||
JP2005075734A (ja) | 光学活性ホモクエン酸の製法 | |
RU2632670C2 (ru) | Способ получения алкил 2-(1,11-диокса-4,8-дитиа-6-азациклотридекан-6-ил)алканоатов | |
ES2708344T3 (es) | Procedimiento para la preparación de hidrocloruro de 4-cianoperidina | |
CN106278968B (zh) | 一种合成硫代氨基酸衍生物的方法 | |
CN104193656B (zh) | 一种β-二羰基砜类化合物及其制备方法 | |
JP2019131510A (ja) | ルビプロストンの製造方法 | |
WO2018188763A1 (en) | New process for the synthesis of firocoxib | |
Zyuzin | 2, 2-Bis (methoxy-and ethoxy-NNO-azoxy) propane-1, 3-diol sulfonates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20170510 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181010 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190627 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190709 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191206 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191224 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6649368 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |